[1] |
Akhsan A,Aryandono T. Prognostic factors of locally advanced breast cancer patients receiving neoadjuvant and adjuvant chemotherapy[J]. Asian Pac J Cancer Prev,2010,11 (3):759-761.
|
[2] |
Khokher S, Mahmood S, Khan SA. Response to neoadjuvant chemotherapy in patients with advanced breast cancer: a local hospital experience[J].Asian Pac J Cancer Prev,2010,11 (2):303-308.
|
[3] |
Gast MC, van Dulken EJ, van Loenen TK, et al. Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling [J].Int J Biol Markers,2009,24(3):130-141.
|
[4] |
梁燕,姜军,柴凡,等.乳腺癌患者与健康人血清蛋白质谱的差异分析[J/CD]. 中华乳腺病杂志:电子版,2009,3(5):535-541.
|
[5] |
Gast MC, Van Gils CH, Wessels LF, et al. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS[J].Oncol Rep,2009,22(1):205-213.
|
[6] |
Ricolleau G, Charbonnel C, Lode L, et al. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prongostic biomarkers in node-negative breast cancer tumors[J].Proteomics,2006,6(6):1963-1975.
|
[7] |
Sauter ER, Davis W, Qin W, et al. Identification of a beta-casein-like peptide in breast nipple aspirate fluid that is associated with breast cancer[J]. Biomark Med,2009,3(5):577-588.
|
[8] |
Gast MC, van Gils CH, Wessels LF, et al. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS) [J]. Clin Chem Lab Med,2009,47(6):694-705.
|
[9] |
应敏刚, 陈强, 叶韵斌,等. 血清蛋白质谱诊断模型在乳腺癌辅助诊断中的价值[J]. 中华肿瘤杂志,2010,32(9):698-702.
|
[10] |
Gast MC, Schellens JH and Beijnen JH. Clinical proteomics in breast cancer: a review [J]. Breast Cancer Res Treat,2009,116(1):17-29.
|
[11] |
Ushijima M, Miyata S, Eguchi S, et al. Common peak approach using mass spectrometry data sets for predicting the effects of anticancer drugs on breast cancer[J].Cancer Inform,2007,3:285-293.
|
[12] |
Sutton CW,Rustogi N,Gurkan C,et al. Quantitative proteomic profiling of matched normal and tumor breast tissues [J].J Proteome Res,2010,9(8):3891-3902.
|
[13] |
Li Y, Wen Z, Xiao J, et al. Predicting disease-associated substitution of a single amino acid by analyzing residue interactions[J]. BMC Bioinformatics,2011,12:14.
|
[14] |
Deng X, Geng H, Bastola DR, et al. Link test-A statistical method for finding prostate cancer biomarkers [J]. Comput Biol Chem,2006,30(6):425-433.
|
[15] |
Chen WC, Lai CC, Tsai Y, et al. Mass spectroscopic characteristics of low molecular weight proteins extracted from calcium oxalate stones: prelim-inary study [J]. J Clin Lab Anal,2008,22(1):77-85.
|
[16] |
Tewari M, Pradhan S,Singh U,et al. Assessment of predictive markers of response to neoadjuvant chemotherapy in breast cancer [J]. Asian J Surg,2010,33(4):157-167.
|
[17] |
Budczies J, Weichert W, Noske A, et al. Genome-wide gene expression profiling of formalin-fixed paraffin-embedded breast cancer core biopsies using microarrays [J]. J Histochem Cytochem,2011,59(2):146-157.
|
[18] |
Sahab ZJ, Man YG, Semaan SM, et al. Alteration in protein expression in estrogen receptor alpha-negative human breast cancer tissues indicates a malignant and metastatic phenotype [J]. Clin Exp Metastasis,2010,27(7):493-503.
|
[19] |
Gast MC, Engwegen JY, Schellens JH, et al. Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling [J]. BMC Med Genomics,2008,1:4.
|
[20] |
Lu HB, Zhou JH, Ma YY, et al.Five serum proteins identified using SELDI-TOF MS as potential biomarkers of gastric cancer [J]. Jpn J Clin Oncol,2010,40 (4):336-342.
|
[21] |
Apweiler R, Martin MJ, O’Donovan C, et al. The Universal Protein Resource (UniProt) in 2010 [J]. Nucleic Acids Res,2010,38: D142-D148.
|
[22] |
Wang X, Dai S, Zhang Z, et al. Characterization of apolipoprotein A-I as a potential biomarker for cholang-iocarcinoma[J]. Eur J Cancer Care,2009,18(6):625-635.
|
[23] |
Pusztai L, Gregory BW, Baggerly KA, et al. Pharmacoproteomic analysis of prechemo-therapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma [J]. Cancer,2004,100(9):1814-1822.
|
[24] |
Pietrowska M, Polanska J, Marczak L, et al. Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer [J]. J Transl Med,2010,8:66.
|
[25] |
Li J, Orlandi R, White CN, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry [J]. Clin Chem,2005,51(12):2229-2235.
|
[26] |
Ota T, Suzuki Y, Nishikawa T, et al. Complete sequencing and characterization of 21 243 full-length human cDNAs [J].Nat Genet,2004,36(1):40-45.
|
[27] |
Gerhard DS, Wagner L, Feingold EA, et al. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC) [J]. Genome Res,2004,14(10B):2121-2127.
|
[28] |
Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers [J].Science,2006,314(5797):268-274.
|
[29] |
Diss JK, Archer SN, Hirano J, et al. Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines[J]. Prostate,2001,48(3):165-178.
|